Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
212 Leser
Artikel bewerten:
(0)

American Kidney Fund Adds Financial Assistance Program for Post-Transplant Testing for Low-income Patients

Blood tests offer non-invasive alternative to monitor transplanted kidney health

ROCKVILLE, MD / ACCESSWIRE / July 27, 2020 / The American Kidney Fund (AKF) today announced a new financial assistance program for low-income kidney transplant recipients to help them cover the costs of non-invasive blood tests that monitor the health of their transplanted kidney. AKF's Post-Transplant Testing Program will help low-income patients access these innovative tests which can detect early signs of rejection of a transplanted kidney before it happens.

The new AKF program will provide eligible transplant patients-those who have received a kidney transplant within the past 10 years and who have an annual income up to 400% of the federal poverty level-one annual grant up to a maximum of $1,200 to cover their out-of-pocket costs associated with the tests.

Kidney transplant recipients must take immunosuppressive drugs to prevent their immune systems from attacking and damaging their transplant. Even with immunosuppressive regimens, rejection of the organ is always a risk; many kidney transplant rejections occur within the first five to 10 years. Sophisticated blood tests can detect the very earliest signs of rejection or other injury to the transplanted kidney by identifying DNA fragments from the donated organ in the recipient's blood.

"Accurate and early diagnosis of rejection or kidney injury in a transplanted kidney gives clinicians the opportunity to intervene before the damage is severe," said LaVarne A. Burton, AKF president and CEO. "Our new Post-Transplant Testing Program helps to ensure that low-income patients are not precluded from getting these diagnostic tests if they cannot afford the out-of-pocket expenses associated with them."

Grant requests must be submitted through AKF's online Grants Management System at gms.kidneyfund.org by the patient, their designated caregiver or their renal professional.

About Us

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation's leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.

Contacts:

Alice Andors
11921 Rockville Pike, Suite 300
Rockville, MD 20852
Senior Director of Communications
Work: 240-292-7053
Mobile: 703-609-6085
aandors@kidneyfund.org
https://www.kidneyfund.org/

SOURCE: American Kidney Fund



View source version on accesswire.com:
https://www.accesswire.com/598815/American-Kidney-Fund-Adds-Financial-Assistance-Program-for-Post-Transplant-Testing-for-Low-income-Patients

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.